TEAM - KEITH WILCOXEN

Dr. Wilcoxen joined Hyku as Chief Scientific Officer in March 2025.  Most recently he served as Chief Development Officer at Rome Therapeutics, where he led the advancement of the company’s pipeline programs. Prior to that, he was Senior Vice President of Global Research at Zenas BioPharma,and he held leadership roles at Boston Pharmaceuticals as Vice President of Diligence and Non-Clinical Development, and later as Vice President of Translational Research. Earlier in his career, he held roles of increasing responsibility with TESARO, Eisai, Neurocrine Biosciences, and Pfizer. Dr. Wilcoxen holds a Ph.D. in chemistry from Scripps Research Institute and a B.A. in chemistry from Northwestern University.